Open Nav

Arpeggio Biosciences, Inc.

  • Daniel Weaver, Arpeggio Biosciences, Inc.

Connect to a venture capital community that understands the intrinsic value of our technology

  • Date:Wednesday, October 17
  • Time:2:30 PM - 2:45 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Arpeggio Biosciences delivers novel insights about a compound’s biological mechanism of action and discovers new therapeutically relevant targets. Our technology combines state-of-the-art nascent transcript sequencing with proprietary algorithms to identify the drivers of biological responses to drug treatment and other environmental perturbations. We identify changes in gene expression (mRNA), enhancer activity (eRNA), and transcription factor activity minutes after treatment. No other technology can track these rapid changes and explore longer term impacts of a drug or other biological response. These results provide our collaborators with valuable insight into drug development that can reduce costs and rapidly lead to higher quality drugs candidates. Also, we are building a complete gene network map that correlates disease state, drug sensitivity, and transcription factor activity. We will use these data to identify novel therapeutic targets and molecular diagnostic marke
  • Company Website:www.arpeggiobiosciences.com
  • Company HQ City:Boulder, CO
  • Company HQ Country:United States
  • Company HQ State:Colorado                   
  • CEO/Top Company Official:Daniel Weaver
  • Year Founded:2017
  • Main Therapeutic Focus:Platform for Therapeutics
  • Lead Product in Development :CLARION, our platform for determining biological mechanism of action and network inference
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :0
  • Additional Information/Comments:Our accomplishments and growth to date have been funded from our revenue, without any outside equity capital or debt. We are the only company with the technology and expertise to deliver these services and, as a result, we enjoy a unique position in the marketplace. We will continue to scale as long as we are capturing new collaborators and growing the total addressable market. In parallel, we will continue to leverage CLARION to identify new targets and respective therapeutics for future develop by Arpeggio, either with partners or on our own. We now seek to raise capital to significantly accelerate the development of our proprietary target identification data asset. Our proposed funding strategy would allow us complete the requisite experiments 3 years faster, to identify and confirm high-quality therapeutic targets, and realize significant value for our investors.
  • Previous and Current Investors:N/A, we are seeking our first round of funding.
  • Size of Last Investment Round:N/A, we are seeking our first round of funding.
  • Total Amount Raised to Date, In All Rounds:N/A, we are seeking our first round of funding.
Speakers
Daniel Weaver
Arpeggio Biosciences, Inc.
Back